YOLFTbeta
Dermata Therapeutics Inc

Dermata Therapeutics Inc

DRMA · NASDAQ · Healthcare / Biotechnology

0.6212USD-0.04 (-6.01%)

Price History

Full chart

Market Stats

Previous Close0.6609
Open0.66
Day Range0.5707 – 0.67
52-Week Range0.951 – 5.87
Volume160.61K
Market Cap5.80M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.43
Dividend Yield0.00%
Beta0.69
50-Day Avg1.27
200-Day Avg1.49

About

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Gerald T. Proehl
  • Employees9
  • Headquarters3525 Del Mar Heights Rd., San Diego, CA, United States, 92130, USA
  • Websitehttps://www.dermatarx.com

Leadership

  • Mr. Gerald T. ProehlFounder, President, CEO & Chairman · b. 1959
  • Mr. David F. HaleCo-Founder & Lead Independent Director · b. 1949
  • Ms. Kyri K. Van Hoose CPA, M.B.A.Senior VP & CFO · b. 1978
  • Dr. Christopher J. Nardo M.P.H., Ph.D.Senior VP & Chief Development Officer · b. 1965
  • Mr. Sean ProehlAssociate General Counsel
  • Ms. Kyra PeckaitisVice President of Marketing
  • Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.Senior Vice President of Regulatory Affairs & Quality Assurance · b. 1951

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000
Cost of Revenue1.35K322-----
Gross Profit-1.35K-322-----
Operating Expense4.47M3.17M-----
Operating Income-4.47M-3.17M-7.86M-9.67M-8.04M-12.51M-7.77M
EBITDA-4.47M-3.04M-7.84M-9.67M247.22K-12.29M-7.77M
Net Income-4.72M-3.24M-7.95M-9.61M-7.79M-12.29M-7.56M
R&D2.62M1.61M3.46M5.65M4.07M8.20M2.93M
Interest Expense250.75K197.27K45.61K63.57K---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.07M605.45K11.62M6.94M7.98M3.53M7.86M
Total Liabilities2.28M3.78M1.52M922.63K1.62M1.97M1.64M
Total Equity-210.16K-3.18M10.11M6.02M6.36M1.56M6.22M
Cash1.99M530.40K10.80M6.24M7.44M3.16M7.52M
Total Debt1.28M3.55M-----
Net Debt-708.06K3.02M-10.80M-6.24M-7.44M-3.16M-7.52M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.92M-4.03M-5.69M-8.83M-6.41M-11.16M-7.76M
Financing Cash Flow4.73M2.57M15.96M4.28M7.61M6.89M12.12M
Capital Expenditure0004000
Free Cash Flow-3.92M-4.03M-5.69M-8.83M-6.41M-11.16M-7.76M
Dividends Paid--2.29M----
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF---40.28%----

Earnings

Report DateMar 31, 2020Mar 31, 2021Sep 27, 2021Nov 15, 2021Mar 28, 2022May 16, 2022Aug 15, 2022Nov 10, 2022Feb 21, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 21, 2024May 15, 2024Aug 7, 2024Nov 13, 2024Mar 17, 2025May 7, 2025Aug 13, 2025Nov 14, 2025Mar 27, 2026May 13, 2026Aug 11, 2026Nov 13, 2026
EPS Estimate0.000.00-22.56-600.00-5.68-960.00-768.00-528.00-480.00-397.50-138.00-94.50-0.78-54.00-37.90-26.40-15.00-0.45-2.90-1.59-1.54-0.53-0.55-
EPS Actual-0.74-1.21-11.20-2064.00-4.16-792.00-576.00-480.00-288.00-340.50-94.50-81.00-0.21-4.70-41.80-20.40-13.40-1.25-1.66-1.65-1.52-0.48-0.74-
Surprise--50.35%-244.00%26.76%17.50%25.00%9.09%40.00%14.34%31.52%14.29%73.08%91.30%-10.29%22.73%10.67%-178.11%42.76%-3.77%1.30%9.43%-34.55%-
Timing---After-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap5.80M
Enterprise Value1.14M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.59
EPS-4.43
Book Value0.867
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-7.86M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-183.89%
Return on Assets-89.88%
Shares Outstanding4.96M
Shares Float2.90M
Beta0.69
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 4.00
  • Buy
    1

Ownership Breakdown

Institutions
7.77%
Insiders
27.35%
Retail / Other
64.88%

Top Institutional Holders

  • Geode Capital Management, LLC
    48.33K0.98%
  • UBS Group AG
    35.61K0.72%
  • Welch & Forbes LLC
    20.00K0.40%
  • Advisory Alpha, LLC
    10.00K0.20%
  • Mcf Advisors, LLC
    1.73K0.04%
  • Tower Research Capital LLC
    7160.01%
  • SBI Securities Co Ltd
    1010.00%
  • Citigroup Inc
    10.00%
  • JPMorgan Chase & Co
    00.00%
  • Clear Street Group Inc
    00.00%
  • Barclays PLC
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    19.10K0.39%
  • Fidelity Series Total Market Index
    1.11K0.02%

Stock Splits

  • Aug 1, 20251:10
  • May 16, 20241:15
  • Mar 14, 20231:16